The business model of Codexis Inc is focused on providing sustainable biocatalysis solutions to industries such as pharmaceuticals, food and beverage, and chemicals. Codexis employs proprietary protein engineering technology to create highly efficient biocatalysts that can replace traditional chemical processes, resulting in cost savings, increased product yields, and reduced environmental impact. By collaborating with its customers, Codexis develops customized enzymes and processes that address specific challenges and improve overall efficiency in various manufacturing processes. Codexis aims to offer value-added solutions to help its customers achieve their sustainability goals while maintaining profitability.

Codexis Inc is primarily active in the biotechnology industry.

The main competitors of Codexis Inc in the market include companies such as DSM, Ginkgo Bioworks, and Amyris.

Codexis Inc is a leading protein engineering company based in Redwood City, California. Founded in 2002, Codexis specializes in designing and optimizing enzymes for various industries, including pharmaceuticals, food and beverages, and sustainable chemistry. With a strong focus on biocatalysis, the company utilizes its proprietary CodeEvolver® platform to develop customized enzyme solutions that enhance the manufacturing processes of its clients. Over the years, Codexis has established itself as a key player in the biotech industry, collaborating with global partners and attracting numerous high-profile clients. By leveraging its expertise in directed evolution and protein engineering, Codexis continues to drive innovation and provide sustainable solutions to address complex challenges in different sectors. As a leader in the field, Codexis Inc consistently strives to deliver value and impact through the application of biocatalysis and its cutting-edge enzyme technologies.

Codexis Inc has achieved several significant milestones throughout its history. One notable achievement was the commercialization of its proprietary CodeEvolver® protein engineering platform. This innovation enabled the company to develop and optimize bio-based processes for various industries, including pharmaceuticals, food and beverages, and chemicals. Another milestone was when Codexis partnered with leading companies like Merck, GlaxoSmithKline, and Shell, showcasing its reputation as a trusted collaborator. Additionally, the company's successful initial public offering (IPO) in 2010 marked a major milestone, providing Codexis with the financial resources to further expand its cutting-edge biocatalysis technologies. Overall, Codexis Inc has consistently demonstrated industry leadership and achieved significant progress in advancing sustainable solutions.

Codexis Inc is primarily present in the United States.

Codexis Inc represents a strong commitment to innovation and sustainability in the biotechnology industry. The company's corporate philosophy is centered around delivering transformative solutions for its customers and creating value for its stakeholders. Codexis Inc is dedicated to leveraging its proprietary technologies and expertise to develop and commercialize high-performance enzymes and other bio-based products. By harnessing the power of biocatalysis, the company aims to enable more sustainable manufacturing processes across various sectors. Codexis Inc's steadfast dedication to excellence and its focus on delivering sustainable solutions makes it a prominent player in the biotechnology industry.

Analysts currently set an average price target of 6,71 USD for the Codexis stock (median: 7,14 USD), implying +210,9 % versus the latest price. The consensus is based on 13 analyst ratings.

Codexis Analyytikkojen kursstavoitteet 2026

13 analysts currently rate the Codexis stock: 10 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Codexis to generate revenue of 72,22 M USD and earnings per share of −0,50 USD.

Codexis Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Codexis share trades at 1,89 EUR (2,16 USD).

The Codexis share (CDXS) is listed on 7 stock exchanges, including: NASDAQ (CDXS), Frankfurt (4QK.F), München (4QK.MU), Düsseldorf (4QK.DU), London (0I0X.L), London (0I0X.L), SIX (Zürich) (4QK.SW).

Codexis Inc. is a specialist in enzyme technology, operating since 2002 and based in Redwood City, California. The company's business model includes three main areas: enzyme development, proteins, and research services. By combining its capabilities in enzyme technology and protein engineering, Codexis has created unique solutions tailored to the needs of the biotechnology, chemical, pharmaceutical, and food industries. The core business of Codexis is enzyme development. Codexis manufactures enzymes that help customers improve chemical processes by exhibiting higher activities and selectivities, making the production of chemicals and bioproducts more cost-effective and environmentally friendly. The company has developed a range of enzymes used in industrial biotechnology, including medicines, seed treatments, food and feed additives, as well as detergents and cleaning agents. In addition to enzyme development, Codexis also offers proteins that the company uses for biochemical analysis, diagnostics, and protein production. Another business area of Codexis is the manufacturing of enzymes for use in IVD diagnostics. These enzymes are used in medicine and biotechnology, particularly in clinical diagnostics and quality assurance. Codexis also provides research services based on enzyme and protein engineering solutions. The company's research department specializes in developing high-performance enzymes and proteins that enable a variety of applications. Furthermore, Codexis utilizes its research capabilities to offer contract research services in protein engineering and expression, as well as enzyme screening and optimization. Codexis has also developed fluorescence spectroscopy technology that allows for the real-time measurement of enzyme activity. These advanced enzyme engineering tools are essential for customers looking to optimize their processes and improve cost-effectiveness. In terms of its business model, Codexis generates its revenues primarily through the sale of enzyme products and contract research services. The company also pursues licensing revenue for its technology related to the development and use of enzymes in the industry. The company is committed to maintaining and expanding its competitive position in the field of enzyme and protein engineering technology. Codexis continuously strives to develop promising technologies for its customers and strengthen its research and development in this area. By supporting its customers with its specific, customized solutions and continually investing in research and development, Codexis positions itself as a leading provider of enzyme and protein engineering technologies.

odotettu liikevaihto Codexis on 72,22 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Codexis on −36,85 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Codexis:n hinta-voitto-suhde (P/E) on tällä hetkellä −4,30. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Codexis-osakkeen arvostusta.

Codexis:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,20. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Codexis-osakkeen arvostuskennuslukuna.

Codexis:n Eulpool-laatuscore on 3/10.

Codexis:n ISIN on US1920051067. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Codexis:n WKN on A0Q2S4. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Codexis:n ticker on CDXS. Tämä pörssinoteeraus käytetään Codexis-osakkeiden kauppaan pörssissä.

Codexis maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Codexis kuuluu sektoriin 'Terveydenhuolto'.

Codexis:n osingot jaetaan valuutassa USD.